Literature DB >> 19096841

Comparison of subcutaneous and intraperitoneal injection of D-luciferin for in vivo bioluminescence imaging.

Yusuke Inoue1, Shigeru Kiryu, Kiyoko Izawa, Makoto Watanabe, Arinobu Tojo, Kuni Ohtomo.   

Abstract

PURPOSE: We compared subcutaneous (SC) injection and intraperitoneal (IP) injection of D-luciferin for in vivo bioluminescence imaging (BLI) to determine the utility of SC injection.
METHODS: Mice bearing SC tumours stably expressing firefly luciferase underwent in vivo BLI using SC and IP injection of D: -luciferin. BLI studies were repeated at an interval of 3 h using a given injection route to assess repeatability and using different injection routes to assess correlation. In mice bearing both SC and IP tumours, BLI was performed successively using intravenous (IV), SC, and IP injection of D: -luciferin. Haematological malignancy model mice underwent BLI using SC and IP injection.
RESULTS: In SC tumours, the peak time was slightly shorter and the peak signal was greater using SC injection than using IP injection. The repeatability of determining peak signals was comparable between the two injection routes, and a good correlation was observed between them. In mice bearing both SC and IP tumours, signals from IP tumours relative to those from SC tumours were much greater using IP injection than using IV or SC injection. In the haematological malignancy model, signals from the spleen relative to those from the bone marrow were greater using IP injection than using SC injection.
CONCLUSION: In addition to rare injection failure, the IP injection of D: -luciferin led to the overestimation of signals from IP tissues. For BLI, SC injection was shown to be a convenient alternative to IP injection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19096841     DOI: 10.1007/s00259-008-1022-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  26 in total

1.  Real-time imaging of ligand-induced IKK activation in intact cells and in living mice.

Authors:  Shimon Gross; David Piwnica-Worms
Journal:  Nat Methods       Date:  2005-08       Impact factor: 28.547

Review 2.  Advancing animal models of neoplasia through in vivo bioluminescence imaging.

Authors:  M Edinger; Y-a Cao; Y S Hornig; D E Jenkins; M R Verneris; M H Bachmann; R S Negrin; C H Contag
Journal:  Eur J Cancer       Date:  2002-11       Impact factor: 9.162

3.  Monitoring of disease progression by bioluminescence imaging and magnetic resonance imaging in an animal model of hematologic malignancy.

Authors:  Yusuke Inoue; Kiyoko Izawa; Arinobu Tojo; Yukihiro Nomura; Rieko Sekine; Naoki Oyaizu; Kuni Ohtomo
Journal:  Exp Hematol       Date:  2007-03       Impact factor: 3.084

4.  Bioluminescent evaluation of the therapeutic effects of total body irradiation in a murine hematological malignancy model.

Authors:  Yusuke Inoue; Kiyoko Izawa; Shigeru Kiryu; Seiichiro Kobayashi; Arinobu Tojo; Kuni Ohtomo
Journal:  Exp Hematol       Date:  2008-10-25       Impact factor: 3.084

5.  Cell uptake and tissue distribution of radioiodine labelled D-luciferin: implications for luciferase based gene imaging.

Authors:  K-H Lee; S S Byun; J-Y Paik; S Y Lee; S H Song; Y S Choe; B-T Kim
Journal:  Nucl Med Commun       Date:  2003-09       Impact factor: 1.690

6.  Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model.

Authors:  Wenge Wang; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2003 Mar-Apr       Impact factor: 4.742

7.  ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging.

Authors:  Yimao Zhang; Joseph P Bressler; Jeff Neal; Bachchu Lal; Hyo-Eun C Bhang; John Laterra; Martin G Pomper
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

8.  Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden.

Authors:  Zain Paroo; Robert A Bollinger; Dwaine A Braasch; Edmond Richer; David R Corey; Peter P Antich; Ralph P Mason
Journal:  Mol Imaging       Date:  2004-04       Impact factor: 4.488

9.  Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.

Authors:  H Matthias Buchhorn; Christof Seidl; Roswitha Beck; Dieter Saur; Christos Apostolidis; Alfred Morgenstern; Markus Schwaiger; Reingard Senekowitsch-Schmidtke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-06       Impact factor: 10.057

10.  In vivo bioluminescence imaging of locally disseminated colon carcinoma in rats.

Authors:  S Zeamari; G Rumping; B Floot; S Lyons; F A Stewart
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

View more
  36 in total

1.  Subcutaneous administration of D-luciferin is an effective alternative to intraperitoneal injection in bioluminescence imaging of xenograft tumors in nude mice.

Authors:  Ashraf A Khalil; Mark J Jameson; William C Broaddus; Theodore D Chung; Sarah E Golding; Seth M Dever; Elisabeth Rosenberg; Kristoffer Valerie
Journal:  ISRN Mol Imaging       Date:  2013

2.  ATP-binding cassette transporters modulate both coelenterazine- and D-luciferin-based bioluminescence imaging.

Authors:  Ruimin Huang; Jelena Vider; Inna Serganova; Ronald G Blasberg
Journal:  Mol Imaging       Date:  2011-06       Impact factor: 4.488

3.  Multiple recombinant adeno-associated viral vector serotypes display persistent in vivo gene expression in vector-transduced rat stifle joints.

Authors:  Jeffrey B Mason; Brittney L Gurda; Julie B Engiles; Kurt D Hankenson; James M Wilson; Dean W Richardson
Journal:  Hum Gene Ther Methods       Date:  2013-06       Impact factor: 2.396

4.  Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas.

Authors:  Margaret Folaron; Mukund Seshadri
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

5.  Use of luciferase probes to measure ATP in living cells and animals.

Authors:  Giampaolo Morciano; Alba Clara Sarti; Saverio Marchi; Sonia Missiroli; Simonetta Falzoni; Lizzia Raffaghello; Vito Pistoia; Carlotta Giorgi; Francesco Di Virgilio; Paolo Pinton
Journal:  Nat Protoc       Date:  2017-07-06       Impact factor: 13.491

6.  Continuous, real-time bioimaging of chemical bioavailability and toxicology using autonomously bioluminescent human cell lines.

Authors:  Tingting Xu; Dan M Close; James D Webb; Sarah L Price; Steven A Ripp; Gary S Sayler
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2013-05-29

7.  In vitro and in vivo direct monitoring of miRNA-22 expression in isoproterenol-induced cardiac hypertrophy by bioluminescence imaging.

Authors:  Yingfeng Tu; Lin Wan; Dongliang Zhao; Lihong Bu; Dandan Dong; Zheyu Yin; Zhen Cheng; Baozhong Shen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-07       Impact factor: 9.236

8.  Continuous and Real-Time In Vivo Autobioluminescent Imaging in a Mouse Model.

Authors:  Derek Yip; Andrew Kirkpatrick; Tingting Xu; Tom Masi; Stacy Stephenson; Steven Ripp; Dan Close
Journal:  Methods Mol Biol       Date:  2020

9.  Imaging beta-galactosidase activity in human tumor xenografts and transgenic mice using a chemiluminescent substrate.

Authors:  Li Liu; Ralph P Mason
Journal:  PLoS One       Date:  2010-08-06       Impact factor: 3.240

10.  Autonomous bioluminescent expression of the bacterial luciferase gene cassette (lux) in a mammalian cell line.

Authors:  Dan M Close; Stacey S Patterson; Steven Ripp; Seung J Baek; John Sanseverino; Gary S Sayler
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.